Table 10.
American College of Rheumatology (ACR) criteria scores of 20, 50, and 70 data used in the monotherapy network meta-analysis
| Study | Population for sensitivity analysis | Treatment group for analysis | Follow-up (weeks) | Number of patients | ACR 20 n (%) | ACR 50 n (%) | ACR 70 n (%) |
|---|---|---|---|---|---|---|---|
| Combe et al42 | DMARD exp | SUL | 24 | 50 | 14 (28.0%) | 7 (14.0%) | 1 (2.0%) |
| ETN 2 × 25 mg/week | 24 | 103 | 76 (73.8%) | 48 (46.6%) | 22 (21.4%) | ||
| Edwards et al81 | MTX exp | MTX | 24 | 40 | 15 (37.5%) | 5 (12.5%) | 2 (5.0%) |
| RTX 2 × 1000 mg | 24 | 40 | 26 (65.0%) | 13 (32.5%) | 6 (15.0%) | ||
| Johnsen et al73 | DMARD exp | ETN 2 × 25 mg/week | 24 | 26 | 17 (65.4%) | 10 (38.5%) | 4 (15.4%) |
| ETN 2 × 50 mg/week | 24 | 51 | 30 (58.8%) | 19 (37.3%) | 8 (15.7%) | ||
| Kameda et al46 | MTX exp | ETN 2 × 25 mg/week | 24 | 74 | 47 (63.5%) | 35 (47.3%) | 19 (25.7%) |
| ETN 2 × 25 mg/week + MTX | 24 | 77 | 70 (90.9%) | 50 (64.9%) | 30 (39.0%) | ||
| Keystone et al82 | MTX exp | MTX | 24 | 133 | 37 (27.8%) | 18 (13.5%) | 7 (5.3%) |
| GOL 100 mg/4 weeks | 24 | 133 | 47 (35.3%) | 26 (19.5%) | 15 (11.3%) | ||
| Maini et al51 | MTX exp | TOC 2 mg/kg/4 weeks | 16 | 53 | 16 (30.2%) | 3 (5.7%) | 1 (1.9%) |
| TOC 4 mg/kg/4 weeks | 16 | 54 | 33 (61.1%) | 15 (27.8%) | 3 (5.6%) | ||
| TOC 8 mg/kg/4 weeks | 16 | 52 | 33 (63.5%) | 21 (40.4%) | 8 (15.4%) | ||
| MTX | 16 | 49 | 20 (40.8%) | 14 (28.6%) | 8 (16.3%) | ||
| Miyasaka74 | DMARD exp | PLA | 24 | 87 | 12 (13.8%) | 5 (5.7%) | 1 (1.1%) |
| ADA 20 mg/2 weeks | 24 | 87 | 25 (28.7%) | 14 (16.1%) | 9 (10.3%) | ||
| ADA 40 mg/2 weeks | 24 | 91 | 40 (44.0%) | 22 (24.2%) | 11 (12.1%) | ||
| ADA 80 mg/2 weeks | 24 | 87 | 44 (50.6%) | 28 (32.2%) | 13 (14.9%) | ||
| Moreland et al80 | DMARD exp | PLA | 12 | 44 | 6 (13.6%) | 3 (6.8%) | NR |
| ETN 0.25 mg/m2 | 12 | 46 | 15 (32.6%) | 4 (8.7%) | NR | ||
| ETN 2 mg/m2 | 12 | 46 | 21 (45.7%) | 10 (21.7%) | NR | ||
| ETN 16 mg/m2 | 12 | 44 | 33 (75.0%) | 25 (56.8%) | NR | ||
| Moreland et al75 | DMARD exp | PLA | 24 | 80 | 9 (11.3%) | 4 (5.0%) | 1 (1.3%) |
| ETN 2 × 10 mg/week | 24 | 76 | 39 (51.3%) | 18 (23.7%) | 7 (9.2%) | ||
| ETN 2 × 25 mg/week | 24 | 78 | 46 (59.0%) | 31 (39.7%) | 12 (15.4%) | ||
| Nishimoto et al77 | MTX exp | PLA | 12 | 53 | 6 (11.3%) | 1 (1.9%) | 0 (0.0%) |
| TOC 4 mg/kg/4 weeks | 12 | 54 | 31 (57.4%) | 14 (25.9%) | 11 (20.4%) | ||
| TOC 8 mg/kg/4 weeks | 12 | 55 | 43 (78.2%) | 22 (40.0%) | 9 (16.4%) | ||
| Nishimoto et al76 | MTX exp | MTX | 24 | 66 | 17 (25.8%) | 7 (10.6%) | 4 (6.1%) |
| TOC 8 mg/kg/4 weeks | 24 | 61 | 49 (80.3%) | 30 (49.2%) | 18 (29.5%) | ||
| van de Putte et al79 | DMARD exp | PLA | 12 | 70 | 7 (10.0%) | 1 (1.4%) | 0 (0.0%) |
| ADA 20 mg/week | 12 | 72 | 36 (50.0%) | 17 (23.6%) | 8 (11.1%) | ||
| ADA 40 mg/week | 12 | 70 | 40 (57.1%) | 19 (27.1%) | 7 (10.0%) | ||
| ADA 80 mg/week | 12 | 72 | 39 (54.2%) | 14 (19.4%) | 6 (8.3%) | ||
| van de Putte et al78 | DMARD exp | PLA | 26 | 110 | 21 (19.1%) | 9 (8.2%) | 2 (1.8%) |
| ADA 20 mg/2 weeks | 26 | 106 | 38 (35.8%) | 20 (18.9%) | 9 (8.5%) | ||
| ADA 20 mg/week | 26 | 112 | 44 (39.3%) | 23 (20.5%) | 11 (9.8%) | ||
| ADA 40 mg/2 weeks | 26 | 113 | 52 (46.0%) | 25 (22.1%) | 14 (12.4%) | ||
| ADA 40 mg/week | 26 | 103 | 55 (53.4%) | 36 (35.0%) | 19 (18.4%) | ||
| van Riel et al47 | MTX exp | ETN 2 × 25 mg/week | 16 | 160 | 114 (71.3%) | 67 (41.9%) | 28 (17.5%) |
| ETN 2 × 25 mg/week + MTX | 16 | 155 | 104 (67.1%) | 62 (40.0%) | 29 (18.7%) | ||
| TEMPO (sensitivity analysis only; data from CSR)55 | Mixed naïve and experienced population | MTX | 24 | 228 | 168 (73.7%) | 93 (40.8%) | 35 (15.4%) |
| ETN 2 × 25 mg/week | 24 | 231 | 159 (68.8%) | 90 (39.0%) | 38 (16.5%) |
Notes: Treatments in bold are treatments of interest (licensed doses); PLA is the reference treatment.
Abbreviations: ADA, adalimumab; CSR, corporate social responsibility; DMARD, disease-modifying antirheumatic drug; ETN, etanercept; exp, experienced; GOL, golimumab; INF, infliximab; MTX, methotrexate; NR, not reported; PLA, placebo; RTX, rituximab; SUL, sulfasalazine; TOC, tocilizumab.